GLUE - TOP PICK - MRT-8102 (NEK7) Deep Dive Highlights Multiple Key Opportunities for Potential Value Creation This Year; PT to $35

研报英文原文证据摘录

GLUE - TOP PICK - MRT-8102 (NEK7) Deep Dive Highlights Multiple Key Opportunities for Potential Value Creation This Year; PT to $35

evidence in support of the "inflammation Monte Rosa Therapeutics, Inc.

Sector: Biotechnology hypothesis" of atherosclerosis. IL-6 is a downstream component of the NLRP3/inflammasome pathway and ZEUS is the key Phase 3

test of that hypothesis, which could reshape cardiovascular prevention guidelines, validating an entire new class of therapeutics. A key

Company Update hypothesis has been that NEK7/NLRP3 inhibitors may be mechanistically most compelling here, given upstream and potentially more

Share Price $22.29 physiologically "balanced" inhibition of this pathway via orally delivered product candidates. We believe GLUE shares could double

by YE26 in a bull-case scenario with potential for 50% downside in a bear case. We've updated our GLUE model, incorporating more Price Target $35.00

specific risk-adjusted estimates for MRT-8102 across Phase 2 target indications ASCVD, gout and HS. Our PT moves to $35 (from Prior $30.00

$30). We're also elevating GLUE to a "top-pick" for 2H26.

Market Data

52-Week Range $4.12 - $25.77 MRT-8102 is GLUE's potentially differentiated NLRP3 pathway inhibitor and main near-term value driver. We believe that the

majority of GLUE's current ~$1.3Bn EV ($1.9Bn market valuation) and much of the near-term upside potential is tied to MRT-8102. Recall, Dividend $0.00

MRT-8102 is a first-in-class molecular glue degrader of NEK7. NEK7 degradation selectively inhibits NLRP3 inflammasome assembly, Shares Out (M) 84.5

which is a mechanistically differentiated approach from direct NLRP3 kinase inhibitors (e.g., BIOA, LLY, NVS, RHHBY, AZN, NodThera Market Cap (M) $1,883 [private], etc.) to block this pathway (see Exhibit 1).